Burnmeister data from 2012 showed a local control benefit for radiation therapy in selected patients, but that was without immunotherapy. What specific clinico-pathologic factors (e.g., number of nodes, desmoplastic histology, primary site) guide your decision to recommending the addition of RT to standard-of-care immunotherapy, and how would you sequence therapy?
I agree that the role of adjuvant radiation is unc...
There is no singular policy that we uniformly adhe...
What is your adjuvant dose and fractionation for r...